BIO-Europe in Berlin Nov 6-8, meet Lipum there.

Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén at BIO-Europe 2017 in Berlin, Nov 6-8. We will tell you more on our novel target Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these diseases.

Lipum has collected original research data proving the efficacy of the compound in several established arthritis models. The BSSL antibodies effectively block human inflammatory cell migration. We are currently developing a humanized monoclonal antibody that target BSSL and our candidate drug will then be subject for toxicological tests and clinical trials. Lipum is actively seeking partners for a faster development, read more here

2017-11-02T10:58:13+00:00